** Shares of Neurizon Therapeutics NUZ.AX rise 12% to A$0.14
* Stock hit highest level since Jan.20
** Biotech firm receives U.S. patent for NUZ-001 for treatment of neurodegenerative diseases
** Adds, patent grant follows FDA's Orphan Drug Designation for NUZ-001 in May 2024
** Stock down 26.5% this year as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。